Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep131 | Calcium and Bone | ECE2021

Hypercalciuria and associated mineral metabolism disorders in osteopenic/osteoporotic patients: effects of treatment with thiazide diuretics

Nicoli Federico , Dito Giorgia , Guabello Gregorio , Longhi Matteo , Corbetta Sabrina

Hypercalciuria may represent a challenge during the workup for osteoporosis management. The present study aimed: 1) to describe the phenotype associated with hypercalciuria in vitamin D-repleted (serum 25OHD > 20 ng/ml) osteopenic/osteoporotic patients, focusing on kidney, bone and mineral metabolic features; 2) to analyze the effects of thiazides and anti-resorptive drugs on urine calcium excretion (UCa) and mineral metabolism markers. Seventy patients (67 postmenopausal ...

ea0094p365 | Neuroendocrinology and Pituitary | SFEBES2023

Suboptimal treatment of acromegaly potentially leading to onset and progression of B cell lymphoma

Iacuaniello Davide , Majeed Waseem , Pathmanaban Omar , Roncaroli Federico , Kearney Tara

Acromegaly is a rare endocrine disorder mostly caused by a growth hormone (GH)-secreting pituitary adenoma. The aim of treatment is to normalize GH/IGF1 levels to limit disease burden. Growth hormone hypersecretion is associated with an increased cancer risk; cases of Acromegaly complicated by lymphoma have been reported. We share a clinical case characterized by suboptimal treatment, potentially leading to advancing orbital lymphoma. This 49-year-old man was diagnosed with Ac...

ea0099p602 | Late-Breaking | ECE2024

A rare case of concurrent pituitary adenoma with granulomata

Choudhary Yashaswini , Sankar Adhithya , Roncaroli Federico , Majeed Waseem

Case presentation: A 60-year-old gentleman presented with altered vison. Past medical history included ulcerative colitis, henoch-schonlein purpura (HSP) and Graves’ disease. Family history included a brother that underwent surgery for a pituitary macroadenoma. Pituitary MRI identified a 27 × 16 × 20 mm macroadenoma with chiasmal compression. Perimetry demonstrated bitemporal hemianopia. Clinical assessment showed no stigmata of endocrinopathy. Pituitary functio...

ea0032p519 | Endocrine tumours and neoplasia | ECE2013

mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids

Gagliano Teresa , Bellio Mariaenrica , Gentilin Erica , Mole Daniela , Tagliati Federico , Schiavon Marco , Cavallesco Narciso Giorgio , Calabrese Fiorella , Ambrosio Maria Rosaria , Rea Federico , Uberti Ettore degli , Zatelli Maria Chiara

Background: Bronchial carcinoids (BCs) are rare neuroendocrine tumors that are still orphan of medical treatment. Human BC primary cultures may display resistance to everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), in terms of cell viability reduction.Aim: To assess whether the novel dual PI3K/mTOR inhibitor, NVP-BEZ235, may be effective in everolimus-resistant human BC tissues and cell lines. In addition, we search for possible mark...

ea0098c42 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Treatment with Lutetium in a real-world setting: How does it affect patient experience and their time-toxicity?

Romina Luca Maria , Cecilia Vazquez Eliana , Waisberg Federico , Catani Greta , Oviedo Ana , Musumeci Martina , Rodriguez Andres , Bortz Marcos , Esteso Federico , Chacon Matias , Manuel Oconnor Juan , Racioppi Silvina

Background: Lutetitum-177 (Lu-DOTATE) is an approved treatment regimen for patients with advanced neuroendocrine tumors (NETs). Improving patient experience is one of main goals of a cancer treatment plan. "Time-toxicity" describes the period that patients spend in doing administrative or medical procedures, including medical visits, scans, lab analyses, emergency room admissions, drug applications and hospitalizations. Modern therapies are usually approved after an im...

ea0081p659 | Pituitary and Neuroendocrinology | ECE2022

Evaluation of copeptin levels during glucagon stimulation test in children with suspected growth hormone deficiency

Ferrante Emanuele , Giacchetti Federico , Indirli Rita , Profka Eriselda , Rodari Giulia , Giavoli Claudia , Mantovani Giovanna , Arosio Maura

Introduction: Glucagon stimulation test is one of the recommended growth hormone provocation tests for diagnosing growth hormone deficiency in children. In adult patients, recent data showed that glucagon administration is able to stimulate the release of copeptin, the stable C-terminal glycopeptide of the AVP prohormone whose evaluation during hypertonic saline infusion represents the gold standard for the differential diagnosis of polyuria/polydipsia. However, similar data o...

ea0081ep646 | Pituitary and Neuroendocrinology | ECE2022

A clinical case of hypogonadism and anosmia associated with a new mutation of the KAL1/ANOS1 gene: a preliminary report

Del Prete Michela , Sacco Gianleone Di , Bonomi Marco , Vignati Federico , Muratori Fabrizio , Persani Luca

Introduction: Kallmann syndrome (KS) is a genetic condition characterized by the association of anosmia or hyposmia and GnRH deficiency resulting in congenital hypogonadotropic hypogonadism (CHH). Different genes can be implicated in KS, and the most frequent allelic variant occurs in the KAL1/ANOS1 gene in the X-linked form. Differential diagnosis is often made with other rare genetic diseases as CHARGE syndrome (CS) that includes hypogonadism, hyposmia and several organ defe...

ea0081ep754 | Pituitary and Neuroendocrinology | ECE2022

Early diagnostic tools in milder forms of central hypothyroidism in patients harbouring a pituitary adenoma: cross-sectional study on 142 patients from a single tertiary center

Galazzi Elena , Nicoli Federico , Carrara Silvia , Milan Chiara , Fatti Letizia Maria , Moro Mirella , Persani Luca

Introduction: Milder forms of central hypothyroidism (CeH) are still challenging to diagnose due to absence of gold standards, wide variability of fT4 values and aspecificity of symptoms. We aimed to find diagnostic clues at diagnosis (pituitary lesion dimensions, other hormonal deficit) and during long-term follow-up, guiding the clinician to a precocious diagnosis of CeH.Study: 142 patients harbouring a pituitary adenoma with complete pituitary assessm...

ea0081ep867 | Reproductive and Developmental Endocrinology | ECE2022

Real-world evidence of follicle stimulating hormone effectiveness in male idiophatic infertility

Romeo Marilina , Spaggiari Giorgia , Nuzzo Federico , R.M. Granata Antonio , Simoni Manuela , Santi Daniele

Introduction: Male idiopathic infertility represents a therapeutic challenge for physicians, since a targeted aetiological treatment does not exist. Several hormonal and non-hormonal therapies have been proposed so far to increase pregnancy rates. Among hormonal therapies, exogenous follicle-stimulating hormone (FSH) administration shows the most convincing physiological rationale in the face of a clinical efficacy below expectations. Indeed, from evidences available in the li...

ea0050oc1.6 | Early Career Oral Communications | SFEBES2017

Investigating the role of AIP in mouse pituitary adenoma formation

Solomou Antonia , Herincs Maria , Roncaroli Federico , Vignola Maria Lillina , Gaston-Massuet Carles , Korbonits Marta

Introduction: Mutations in the aryl hydrocarbon receptor-interacting protein (AIP) predispose humans to pituitary adenomas, mostly GH and sometimes prolactin-secreting adenomas. Rodent models of heterozygous AIP loss provided mixed results, with little phenotype in heterozygote global knockouts to 80% in somatotroph-specific homozygote knockout animals. However, human patients with an AIP mutation often have mixed GH-PRL adenomas and, in a smaller pr...